NCT01959594View on ClinicalTrials.gov

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Healthy
Interventions
DRUG

3 mg PF-06412562

oral dosing of 3 mg PF-06412562 tablets three times a day for 14 days

DRUG

10 mg PF-06412562

oral dosing of 10 mg PF-06412562 tablets three times a day for 14 days

DRUG

25 mg PF-06412562

oral dosing of 25 mg PF-06412562 tablets three times a day for 14 days

DRUG

PF-06412562 TBD mg

oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts

DRUG

PF-06412562 TBD mg

oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts

Trial Locations (1)

06511

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01959594 - A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter